Cas:904813-89-4 2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine manufacturer & supplier

Chemical Name:2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine

CAS.NO:904813-89-4

Synonyms:gl-0404;2-benzo[1,3]dioxol-5-yl-3-bromo-imidazo[1,2-a]pyridine

Molecular Formula:C₁₄H₉BrN₂O₂

Molecular Weight:317.13700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.71g/cm3

Index of Refraction:1.734

PSA:35.76000

Exact Mass:315.98500

LogP:3.49250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like gl-0404 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-benzo[1,3]dioxol-5-yl-3-bromo-imidazo[1,2-a]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,gl-0404 Use and application,2-benzo[1,3]dioxol-5-yl-3-bromo-imidazo[1,2-a]pyridine technical grade,usp/ep/jp grade.

Related News: CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion. 2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine manufacturer It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305. 2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine supplier It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305. 2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine vendor Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. 2-(1,3-benzodioxol-5-yl)-3-bromoimidazo[1,2-a]pyridine factory It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.